KURA Stock Forecast: Kura Oncology, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$6.91
−5.99% on the day

The median 12-month analyst price target for Kura Oncology, Inc. is $28. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 53 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$675.3M
Ticker Nerd rank
53/ 100
Median analyst target
$28
Analysts covering
16
Revenue$20.9M+36.5% y/y
Operating income−$73.0M
Net income−$68.3M
Free cash flow−$63.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.1%
1M
−30.8%
YTD
−33.5%
1Y
−37.1%
From 52W high
−49.2%
From 52W low
+1.6%
$7
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Kura Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
53/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
92
Value
71
Momentum
63
Volatility
62
Quality
54
Revisions
42
Issuance
28
Growth
19

Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (19): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KURA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KURA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Jan 26Apr 26Jul 26Oct 26KURAHigh $76Median $28Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
15
Buy
1
Hold
0
Sell
$15
Low
$28
Median
$76
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Oct 2026JP MorganInitiatesOverweight$30
24 Aug 2026CitizensReiteratesMarket Outperform$24
13 Aug 2026WedbushMaintainsOutperform$36 → $38
28 July 2026WedbushReiteratesOutperform$36
15 June 2026CitizensReiteratesMarket Outperform$24
14 Apr 2026Lake StreetInitiatesBuy—
24 Mar 2026MizuhoMaintainsOutperform—
13 Mar 2026UBSMaintainsBuy—
6 Mar 2026WedbushMaintainsOutperform—
13 Jan 2026HC Wainwright & Co.ReiteratesBuy—
13 Jan 2026Leerink PartnersMaintainsOutperform—
24 Nov 2025BarclaysMaintainsOverweight—
14 Nov 2025UBSMaintainsBuy—
14 Nov 2025WedbushMaintainsOutperform—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
20 Oct 2025JMP SecuritiesReiteratesMarket Outperform—
30 Sept 2025HC Wainwright & Co.ReiteratesBuy—
4 Sept 2025GuggenheimInitiatesNeutral—
11 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
26 June 2025Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KURA.

Market Radar

This page is one stock. Monday covers all of them.

KURA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

KURA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Kura Oncology, Inc. returned −37.1% against +6.9% for the S&P 500, dividends included.

KURA vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26KURAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KURA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
8.4×

Cheaper than 13% of US stocks

Price / book
37.3×

Cheaper than 2% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
98.8%

Higher than 99% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−224.9%

Higher than 6% of US stocks

Return on assets
−32.2%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kura Oncology, Inc. has a market value of $675.3M and an enterprise value of $209.0M.

  • Revenue in the twelve months to 30 June 2026: $77.2M. The latest quarter grew 36.5% year on year.

  • Net income over the same four quarters: −$296.8M, a −384.3% net margin.

  • Diluted earnings per share, trailing twelve months: −$3.37.

  • Free cash flow in the twelve months to 30 June 2026: −$117.4M.

  • Shares outstanding: 89.0M.

  • Kura Oncology, Inc. employs 260 people — $297K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

KURA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KURAKura Oncology, Inc.$675.3M53
OLMAOlema Oncology, Inc.$611.8M25
ABUSArbutus Biopharma Corp.$616.2M82
JANXJanux Therapeutics, Inc.$606.3M73
IAMIambic Therapeutics, Inc.$621.4M1
SGMTSagimet Biosciences, Inc.$638.7M35
ANNXAnnexon, Inc.$587.7M39

Take a look at KURA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Kura Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about KURA

What is the KURA stock price forecast for 2026-2027?

The median 12-month analyst price target for Kura Oncology, Inc. is $28, with estimates ranging from $15 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KURA stock a buy right now?

Of the 16 analysts covering Kura Oncology, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kura Oncology, Inc. 53 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KURA?

As at 21 Nov 2026, Kura Oncology, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).

Will KURA stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts is $28, and Ticker Nerd's factor model ranks Kura Oncology, Inc. 53 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KURA stock forecast for 2030?

No analyst covering Kura Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $76 over the next 12 months.

How has KURA stock performed over the past year?

Kura Oncology, Inc. returned -37.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kura Oncology, Inc. do?

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Kura Oncology’s current portfolio centers on precision oncology programs designed to target specific molecular drivers of disease, with an emphasis on hematologic malignancies and selected solid tumors.

Company

About Kura Oncology, Inc.

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Kura Oncology’s current portfolio centers on precision oncology programs designed to target specific molecular drivers of disease, with an emphasis on hematologic malignancies and selected solid tumors. Its pipeline includes small-molecule drug candidates such as ziftomenib, tipifarnib, and KO-2806, which are being evaluated in clinical development for genetically defined patient populations. The company’s work combines drug discovery, biomarker-driven research, and clinical testing to support targeted treatment approaches in oncology. Based in San Diego, California, Kura Oncology operates as a focused biotechnology company within the broader cancer therapeutics market, contributing to the development of specialized therapies for patients with high unmet medical need.

CEO Dr. Troy Edward Wilson J.D., Ph.D. · 260 employees · United States · https://www.kuraoncology.com